Illumina Inc. Keeps Up Its Winning Ways Thanks to NovaSeq Sales Growth
There was plenty to like when Illumina (NASDAQ: ILMN) reported its second-quarter results in August. Pretty much everything that could go right has gone right for the gene-sequencing leader. Illumina's stock performance so far in 2017 has reflected the good news for the company.
The streak of good news was at risk, however, when Illumina provided an update on its third-quarter performance after the market closed on Tuesday. Any concerns that investors had were alleviated, though: Illumina yet again delivered a strong quarter. Here are the highlights.
Image source: Getty Images.
Source: Fool.com
Illumina Inc. Aktie
112,16 €
-3,35 %
Die Illumina Inc. Aktie steht gut da: Deutlich mehr Buy- als Sell-Einschätzungen in der Community.
Das Kursziel von 160 € für Illumina Inc. impliziert eine deutliche Steigerung um über 20% gegenüber 112.16 €.
